This induces a synthetic lethality in drug-resistant chronic myeloid leukemia in mice[11] and represents a beneficial therapeutic strategy in patients with AML.[12] Trametinib in combination with TKIs may prevent the development of drug resistance through its regulatory molecule MEK. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.